1. Apixaban: an Oral Direct Factor-Xa Inhibitor

   • David Jiménez
   • Roger D. Yusen
   • Eduardo Ramacciotti

   Review 17 February 2012 Pages: 187 - 201

2. Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma

   • Sergio Vázquez
   • Luis León
   • Luis Aparicio

   Review 07 February 2012 Pages: 202 - 217

3. Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

   • Giuseppe Paolisso
   • Matteo Monami
   • Edoardo Mannucci

   Review 08 March 2012 Pages: 218 - 233

4. Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis

   • Machaon M. K. Bonafede
   • Shravanthi R. Gandra
   • Kathleen M. Fox

   Original Research 09 March 2012 Pages: 234 - 248

5. Exploring Channeling Optimized Radiofrequency Energy: a Review of Radiofrequency History and Applications in Esthetic Fields

   • Inna Belenky
   • Ariel Margulis
   • Silviu D. Paun

   Original Research 29 February 2012 Pages: 249 - 266

6. Contribution of Endermology to Improving Indurations and Panniculitis/Lipoatrophy at Glatiramer Acetate Injection Site

   • Delia Rubio Fernández
   • Clara Rodríguez del Canto
   • Rainel Sánchez-De la Rosa

   Original Research 28 February 2012 Pages: 267 - 275

7. Uric Acid is an Important Predictor for Hypertensive Early Atherosclerosis

   • Ruya Mutluay
   • Serpil Muge Deger
   • Sukru Sindel

   Original Research 02 March 2012 Pages: 276 - 286

8. Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients

   • Eishi Baba
   • Hiromitsu Fujishima
   • Koichi Akashi

   Original Research 10 February 2012 Pages: 287 - 296